
Opinion|Videos|March 18, 2026
How Clinical Trial Data Have Shaped Amivantamab Use in Practice for EGFR-Mutated NSCLC
Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss trial data informing amivantamab use in EGFR-mutated NSCLC.
Advertisement
Episodes in this series

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, review findings from the MARIPOSA, COCOON, and PALOMA-3 trials and their impact on clinical practice regarding the use of amivantamab in EGFR-mutated non–small cell lung cancer. Spira discusses how cumulative efficacy, CNS activity, and safety data have strengthened the rationale for amivantamab plus lazertinib in the frontline setting. Raez highlights patient subsets, including those with TP53 co-mutations or CNS metastases, in whom combination strategies may offer particular clinical benefit.
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

